In a B16-F10 in vivo syngeneic model, it has already been demonstrated that tumor related effects observed in the SR59230A-treated mice are similar to the results obtained by performing β3-AR siRNA silencing compared to β2-AR silencing [16]; however, a partial involvement of the other β-AR subtypes cannot be excluded. The gene discussed is ADRB3; the disease is neoplasm.